Group One Trading
NKTR icon

Group One Trading’s Nektar Therapeutics NKTR Stock Holding History

Group One Trading’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$288K Sell
4,000
-1,000
-20% -$56.9K ﹤0.01% 3834
2025
Q4 		$211K Sell
5,000
-118,200
-96% -$6.61M ﹤0.01% 4319
2025
Q3 		$7.01M Sell
123,200
-14,700
-11% -$487K 0.01% 1191
2025
Q2 		$3.56M Buy
137,900
+135,700
+6,168% +$1.52M 0.01% 1603
2025
Q1 		$22.4K Buy
+2,200
New +$28.7K ﹤0.01% 5743
2024
Q4 		– Sell
-7
Closed -$130 – 7729
2024
Q3 		$130 Sell
7
-40
-85% -$762 ﹤0.01% 6468
2024
Q2 		$868 Buy
47
+27
+135% +$569 ﹤0.01% 6382
2024
Q1 		$280 Buy
+20
New +$209 ﹤0.01% 6785
2023
Q4 		– Sell
-1,367
Closed -$12.2K – 7907
2023
Q3 		$12.2K Sell
1,367
-40
-3% -$385 ﹤0.01% 6230
2023
Q2 		$12.1K Buy
+1,407
New +$15K ﹤0.01% 6288
2023
Q1 		– Sell
-13
Closed -$452 – 7692
2022
Q4 		$452 Sell
13
-1,000
-99% -$48.4K ﹤0.01% 6958
2022
Q3 		$49K Sell
1,013
-667
-40% -$39.7K ﹤0.01% 5421
2022
Q2 		$96K Sell
1,680
-92,920
-98% -$5.86M ﹤0.01% 5024
2022
Q1 		$7.65M Buy
94,600
+92,460
+4,321% +$13.7M 0.01% 1196
2021
Q4 		$434K Buy
2,140
+1,080
+102% +$234K ﹤0.01% 4295
2021
Q3 		$286K Sell
1,060
-3,060
-74% -$736K ﹤0.01% 4800
2021
Q2 		$1.06M Buy
4,120
+1,860
+82% +$515K ﹤0.01% 3342
2021
Q1 		$678K Sell
2,260
-9,087
-80% -$2.83M ﹤0.01% 3680
2020
Q4 		$2.89M Buy
11,347
+427
+4% +$110K 0.01% 1730
2020
Q3 		$2.72M Sell
10,920
-6,627
-38% -$2.08M 0.01% 1359
2020
Q2 		$6.1M Sell
17,547
-2,033
-10% -$634K 0.03% 691
2020
Q1 		$5.24M Sell
19,580
-24,300
-55% -$7.52M 0.04% 504
2019
Q4 		$14.2M Buy
43,880
+14,400
+49% +$4.18M 0.1% 230
2019
Q3 		$8.05M Buy
29,480
+20,693
+235% +$7.59M 0.07% 362
2019
Q2 		$4.69M Buy
8,787
+940
+12% +$471K 0.04% 552
2019
Q1 		$3.96M Buy
7,847
+2,127
+37% +$1.26M 0.04% 549
2018
Q4 		$2.82M Sell
5,720
-3,673
-39% -$2.22M 0.02% 802
2018
Q3 		$8.59M Sell
9,393
-7,034
-43% -$6M 0.07% 329
2018
Q2 		$12M Buy
16,427
+9,687
+144% +$11.2M 0.1% 200
2018
Q1 		$10.7M Buy
6,740
+3,060
+83% +$3.94M 0.11% 203
2017
Q4 		$3.3M Buy
3,680
+367
+11% +$217K 0.02% 880
2017
Q3 		$1.19M Sell
3,313
-5,647
-63% -$1.77M 0.01% 1427
2017
Q2 		$2.63M Sell
8,960
-3,713
-29% -$1.07M 0.03% 792
2017
Q1 		$4.46M Buy
12,673
+693
+6% +$156K 0.05% 453
2016
Q4 		$2.21M Buy
11,980
+7,200
+151% +$1.46M 0.02% 867
2016
Q3 		$1.23M Buy
4,780
+2,747
+135% +$707K 0.01% 1133
2016
Q2 		$434K Buy
2,033
+1,900
+1,429% +$425K 0.01% 1842
2016
Q1 		$28K Sell
133
-5,967
-98% -$1.15M ﹤0.01% 3578
2015
Q4 		$1.54M Buy
6,100
+3,527
+137% +$725K 0.02% 1031
2015
Q3 		$423K Sell
2,573
-247
-9% -$43.7K 0.01% 1910
2015
Q2 		$529K Sell
2,820
-3,853
-58% -$663K 0.01% 1734
2015
Q1 		$1.1M Buy
6,673
+3,386
+103% +$696K 0.02% 1009
2014
Q4 		$764K Buy
3,287
+214
+7% +$45.7K 0.01% 1237
2014
Q3 		$556K Sell
3,073
-200
-6% -$38.3K 0.01% 1538
2014
Q2 		$629K Buy
3,273
+1,166
+55% +$206K 0.01% 1466
2014
Q1 		$383K Sell
2,107
-1,226
-37% -$243K 0.01% 1864
2013
Q4 		$568K Sell
3,333
-9,267
-74% -$1.49M 0.01% 1576
2013
Q3 		$1.98M Buy
12,600
+8,540
+210% +$1.58M 0.04% 569
2013
Q2 		$703K Buy
+4,060
New +$623K 0.02% 1083

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Group One Trading's NKTR Position: Q1 2026 in Review

Group One Trading increased its Nektar Therapeutics (NKTR) stake by 311% in Q1 2026, buying an estimated $256K and bringing the position to 5,949 shares worth $428K. The position accounts for ﹤0.01% of the portfolio, ranked #3485.

Group One Trading first reported a position in NKTR in Q2 2013 and has held it in 40 quarters since. The position peaked at $14.8M in Q1 2018. 215 funds tracked by Wall St. Rank hold NKTR as of Q1 2026.

  • Group One Trading held 5,949 shares of Nektar Therapeutics worth $428K as of Q1 2026.
  • Group One Trading bought 4,501 Nektar Therapeutics shares in Q1 2026, an estimated $256K.
  • Nektar Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q1 2026, its #3485 holding.
  • Group One Trading first reported a position in Nektar Therapeutics in Q2 2013 and has held it in 40 quarters since.
  • Group One Trading's Nektar Therapeutics position peaked at $14.8M in Q1 2018.
  • 215 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2026.

Based on Group One Trading's 13F filing for Q1 2026, filed 13 May 2026.